| 1 |
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension [J]. Nat Rev Nephrol, 2020, 16(4): 223-237.
|
| 2 |
Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension:An overview [J]. Drugs, 1990, 2: 1-8.
|
| 3 |
Granger JP, Schnackenberg CG. Renal mechanisms of angiotensin Ⅱ-induced hypertension [J]. Semin Nephrol, 2000, 20(5): 417-425.
|
| 4 |
Miura SI, Matsuo Y, Seumatsu Y. Renin-angiotensin-aldosterone system and its relation to hypertension [J]. Hypertens Res, 2025, 48(8): 2209-2217.
|
| 5 |
Qi J, Yu XJ, Shi XL, et al. NF-κB Blockade in hypothalamic paraventricular nucleus inhibits high-Salt-Induced Hypertension Through NLRP3 and Caspase-1 [J]. Cardiovasc Toxicol, 2016, 16(4): 345-354.
|
| 6 |
李娜, 张岩, 贾营. NF-κB/RBP4信号通路与高血压患者炎症因子变化的相关性 [J]. 临床和实验医学杂志, 2021, 20(24): 2592-2595.
|
| 7 |
Xu ZY, Jing X, Xiong XD. Emerging role and mechanism of the FTO gene in cardiovascular diseases [J]. Biomolecules, 2023, 13(5): 850.
|
| 8 |
Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity [J]. Science, 2007, 316(5826): 889-894.
|
| 9 |
Krüger N, Biwer LA, Good ME, et al. Loss of endothelial FTO antagonizes obesity-induced metabolic and vascular dysfunction [J]. Circ Res, 2020, 126(2): 232-242.
|
| 10 |
刘滴, 李云瞾, 周刚, 等. 去甲基化酶FTO在心血管疾病中的研究进展 [J]. 生命的化学, 2021, 41(3): 552-557.
|
| 11 |
Zhou C, She X, Gu C, et al. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1 [J]. J Clin Invest, 2023, 133(19): e160517.
|
| 12 |
Shan L, Tao M, Zhang W, et al. Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing [J]. Exp Cell Res, 2024, 442(2): 114268.
|
| 13 |
Mo W, Chen Z, Zhang X, et al. N6-Methyladenosine demethylase FTO (fat mass and obesity-associated protein) as a novel mediator of statin effects in human endothelial cells [J]. Arterioscler Thromb Vasc Biol, 2022, 42(5): 644-658.
|
| 14 |
Dubey PK, Patil M, Singh S, et al. Increased m6A-RNA methylation and FTO suppression is associated with myocardial inflammation and dysfunction during endotoxemia in mice [J]. Mol Cell Biochem, 2022, 477(1): 129-141.
|
| 15 |
Zhang F, Zhang L, Wang Y. m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps [J]. Front Med (Lausanne), 2026, 13: 1826751.
|
| 16 |
薛凤麟. NF-κB在AngⅡ调控HUVEC细胞生存/凋亡信号通路中的作用研究[D]. 昆明: 昆明医科大学, 2007.
|
| 17 |
Chen LS, Zhang M, Chen P, et al. The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG [J]. Acta Pharmacol Sin, 2022, 43(5): 1311-1323.
|
| 18 |
Fu C, Jiang W, Wang C, et al. AP001885.4 promotes the proliferation of esophageal squamous cell carcinoma cells by histone lactylation- and NF-κB (p65)-dependent transcription activation and METTL3-mediated mRNA stability of c-myc [J]. Anim Cells Syst (Seoul), 2024, 28(1): 536-550.
|
| 19 |
Gao L, Wang A, Chen Y, et al. FTO facilitates cancer metastasis by modifying the m6A level of FAP to induce integrin/FAK signaling in non-small cell lung cancer [J]. Cell Commun Signal, 2023, 21(1): 311.
|
| 20 |
Yang Z, Xiong M, Tang X, et al. Ginsenoside Rb1 mitigates atherosclerosis in part through modulating FTO-mediated m6A RNA modification in NETs-induced endothelial activation [J]. Front Pharmacol, 2025, 16: 1631076.
|
| 21 |
Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO [J]. Nat Chem Biol, 2011, 7(12): 885-887.
|
| 22 |
Zhao M, Joy J, Zhou W, et al. Transcriptional outcomes and kinetic patterning of gene expression in response to NF-κB activation [J]. PLoS Biol, 2018, 16(9): e2006347.
|
| 23 |
Ajoolabady A, Pratico D, Ren J. Angiotensin Ⅱ: Role in oxidative stress, endothelial dysfunction, and diseases [J]. Mol Cell Endocrinol, 2024, 592: 112309.
|
| 24 |
Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin Ⅱ stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress [J]. Arterioscler Thromb Vasc Biol, 2000, 20(3): 645-651.
|
| 25 |
Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions [J]. Genes Dev, 2012, 26(3): 203-234.
|
| 26 |
Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation [J]. Cold Spring Harb Perspect Biol, 2009, 1(4): a000034.
|
| 27 |
Yu H, Lin L, Zhang Z, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study [J]. Signal Transduct Target Ther, 2020, 5(1): 209.
|
| 28 |
Wang Y, Xiang GS, Kourouma F, et al. Citrobacter rodentium-induced NF-kappaB activation in hyperproliferating colonic epithelia: role of p65 (Ser536) phosphorylation [J]. Br J Pharmacol, 2006, 148(6): 814-824.
|
| 29 |
Kumar A, Negi G, Sharma SS. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence [J]. Diabetes Obes Metab, 2011, 13(8): 750-758.
|
| 30 |
Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs [J]. Oncotarget, 2017, 9(6): 7204-7218.
|
| 31 |
Roundtree IA, Evans ME, Pan T, et al. Dynamic RNA modifications in gene expression regulation [J]. Cell, 2017, 169(7): 1187-1200.
|
| 32 |
He PC, He C. m6A RNA methylation: from mechanisms to therapeutic potential [J]. EMBO J, 2021, 40(3): e105977.
|